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Abstract
Sexually transmitted infections (STIs) unequivocally represent a major public health concern in both industrialized and
developing countries. Previous efforts to develop vaccines for systemic immunization against a large number of STIs in
humans have been unsuccessful. There is currently a drive to develop mucosal vaccines and adjuvants for delivery through
the genital tract to confer protective immunity against STIs. Identification of molecular signatures that can be used as
biomarkers for adjuvant potency can inform rational development of potent mucosal adjuvants. Here, we used systems
biology to study global gene expression and signature molecules and pathways in the mouse vagina after treatment with
two classes of experimental adjuvants. The Toll-like receptor 9 agonist CpG ODN and the invariant natural killer T cell
agonist alpha-galactosylceramide, which we previously identified as equally potent vaginal adjuvants, were selected for this
study. Our integrated analysis of genome-wide transcriptome data determined which signature pathways, processes and
networks are shared by or otherwise exclusive to these 2 classes of experimental vaginal adjuvants in the mouse vagina. To
our knowledge, this is the first integrated genome-wide transcriptome analysis of the effects of immunomodulatory
adjuvants on the female genital tract of a mammal. These results could inform rational development of effective mucosal
adjuvants for vaccination against STIs.
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Introduction
Although the vast majority of human pathogens invade the
body and/or establish infections in the mucosal tissues, only a
handful of mucosal vaccines are currently licensed for human use.
Sexually transmitted infections (STIs) are a major public health
concern in both industrialized and developing countries. Despite
numerous efforts, the human papillomavirus vaccines GardasilH
and CervarixH, given by intramuscular injection, represent the
only human vaccines licensed to prevent an STI. Previous
attempts to develop vaccines for systemic immunization against
other sexually transmitted pathogens in humans have failed [1,2].
This failure has prompted a great interest in developing vaccines
and immunomodulators for delivery via mucosal routes, including
the female genital tract, to confer protective mucosal immunity to
sexually transmitted pathogens. While sexually transmitted
pathogens generate pathogen-specific immune responses, local
administration of non-replicating antigens into the vagina
engenders little to no protective mucosal immune response [3,4].
To overcome this hurdle, immunologic adjuvants with the ability
to mount mucosal immune responses with co-administered
vaccine antigens to confer immunity in the female genital tract
are desirable. However, no mucosal adjuvants are currently
available for human use [5,6]. We have previously shown that the
Toll-like receptor 9 (TLR9) agonist CpG ODN and the invariant
natural killer T (NKT) cell agonist a-galactosylceramide (a-
GalCer) can function as potent vaginal adjuvants when adminis-
tered together with herpes simplex virus type 2 (HSV-2)
glycoprotein D, giving rise to comparable protective immunity
against genital HSV-2 infection and disease in mice [7,8]. Rational
design of effective and safe mucosal adjuvants for human use
requires a thorough understanding of the mode of action of
promising candidate adjuvants in addition to identification of
biomarkers that predict their potency.
Previous efforts to comprehend the effect of immunologic
adjuvants on genome-wide gene expression were performed in
isolated immune cells stimulated with CpG ODN in vitro [9,10] or
muscles and spleens isolated from mice after intramuscular or
intra-peritoneal injection with CpG ODN, alum or MF59 [11,12].
Using real time RT-PCR, we have recently shown that CpG
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cytokines and chemokines in the murine female genital tract
[13]. However, there is a dearth of information on the impact of
mucosal administration of promising experimental adjuvants on
global gene expression in the female genital tract.
To address this issue, we employed a genome-wide transcript
microarray analysis combined with a systems biology approach.
This approach involved an integrated analysis of transcriptome
data to comprehend the molecular correlates of adjuvant efficacy
in the murine female genital tract after treatment with two classes
of experimental mucosal adjuvants, CpG ODN and a-GalCer.
This approach offers the unique advantage of monitoring the
structure and dynamics of multifaceted cell-to-cell interactions in
vivo.
We were able to show that vaginal administration of CpG ODN
generated a rapid induction in the expression of a large number of
genes in the murine vagina between 4 h and 48 h after adjuvant
delivery. a-GalCer, however, created a delayed and transient gene
expression induction. The expression of 343 genes was commonly
up-regulated in the vagina after vaginal delivery of CpG ODN or
a-GalCer. Integrated bio-functionality analyses identified different
pathways involved in innate immune responses by the two
adjuvants. However, ‘‘inflammatory response’’ was found as the
main bio-function induced by both CpG ODN and a-GalCer, and
IFN-c was identified as the main interactor of the bio-function
‘‘inflammatory response’’ shared by both adjuvants. In addition,
analyses of the kinetics of the gene expression revealed highly
interconnected genes that may play important roles in adjuvant
efficacy.
This study showed that 2 classes of candidate vaginal adjuvants,
CpG ODN and a-GalCer, share molecular signatures that may
contribute to their adjuvant efficacy in the female genital tract. To
our knowledge, this is the first report that identifies genome-wide
molecular correlates for adjuvant efficacy in the mammalian
female genital tract.
Materials and Methods
Animal experiments
The study was approved by the Ethical Committee for Animal
Experimentation in Gothenburg, Swedish Animal Welfare
Authority (djurskyddsmyndigheten) with permit number 267-09.
Eight-week-old female C57Bl/6 mice (Charles River, Germany)
were used for this study. The mice were kept under specific
pathogen-free conditions in IVC cages with unlimited access to
food and water and under constant humidity, temperature and a
12-h dark/light cycle at the Experimental Biomedicine Animal
Facility, Sahlgrenska Academy, at the University of Gothenburg.
Isoflourane (Baxter Medical AB) was used to anesthetize the mice.
To synchronize estrus cycles, all mice were injected subcutane-
ously with 3 mg of Depo-Provera (DP, Pfizer), a long-lasting
progestin, in 150 ml of sterile phosphate-buffered saline (PBS).
CpG ODN 1826 (TCC ATG ACG TTC CTG ACG TT,
hereafter CpG ODN), a 20-mer containing two copies of optimal
mouse CpG ODN motifs with complete phosphorothioate
backbones, was purchased from Operon Biotechnologies GMBH,
Germany and reconstituted in PBS. a-GalCer (Alexis Biochem-
icals) was stored in chloroform methanol 2:1 (vol/vol) and after
evaporation, reconstituted in PBS/Tween 0.5% prior to use. Six
days after DP treatment, mice were intravaginally (i.vag.)
administered with a single dose of either CpG ODN (30 mg) or
a-GalCer (5 mg) in 19 ml. These reagent doses were previously
shown to function as potent vaginal adjuvants. Together with
HSV-2 gD antigen, they induced comparable levels of protective
immunity in the mouse vagina against genital herpes infection
[7,8]. Control groups were given the same volume of the PBS or
PBS/Tween 0.5% reagent diluents i.vag. Whole mouse vaginas
(cut right below the cervix) were aseptically removed at different
time points after vaginal administration of the adjuvants and
subjected to microarray analysis, cytokine assessment of the tissue
extract or flow cytometric analysis, as explained below.
Genome wide expression microarray
Whole mouse vaginas were collected in RNAlater
TM (QIAGEN
GmbH, Hilden, Germany) at 4 h, 24 h and 48 h after vaginal
administration. Total RNA was extracted using the RNeasy mini
kit (QIAGEN) following the manufacturer’s protocol with an extra
DNase elimination step during the last wash using the RNase-Free
DNase kit (Qiagen). RNA quality was assessed with an Agilent
2100 BioAnalyzer (Agilent Technologies, Paolo Alto, CA) and
visualized on a 2% agarose gel. Only good quality RNA samples
were used for further processing. Two hundred nanograms of each
sample were prepared and hybridized to Affymetrix Mouse Gene
1.0 ST arrays according to Affymetrix’s recommended protocol
(GeneChipH Whole Transcript (WT) Sense Target Labeling
Assay, 701880 Rev. 5). Hybridization and analysis were performed
according to the manufacturer’s instructions at the SCIBLU
Genomics core facility (Swegene Centre for Integrative Biology at
Lund University, Sweden).
Data acquisition and analysis of transcriptome data
We first evaluated the intrinsic variability in the transcriptome
data. Briefly, raw intensity files (CEL) were normalized and
processed together, and both Probe Logarithmic Intensity Error
(PLIER) with iterative algorithm [14] and quantile normalization
[15] were chosen to identify the expression signal. The intrinsic
variability of the data was evaluated by singular value decompo-
sition (SVD), and first three left Eigen arrays were illustrated in a
pseudo-three dimensional plot (the third dimension is represented
by the dot size). Significant differences in gene expression between
CpG ODN and PBS and between a-GalCer and PBS/Tween
0.5% at each given time point after treatments, i.e., 4 h, 24 h and
48 h, were evaluated using Student’s t-test. The calculated p-
values were transformed into Q-values by correcting for multiple
testing using methods described by Benjamini and Hochberg [16].
To identify cellular processes and adaptations in response to the
treatments, statistical Q-values were mapped in the context of
Gene Ontology (GO) biological networks and pathways [17–18]
using a reporter algorithm [19,20]. Q-values, log 2 fold changes,
the pathway and GO networks including their associated gene
members used for the integration analysis is provided in Table S1.
P-values#0.001 from the reporter algorithm were used in
hierarchical clustering to determine the pattern of responses, and
the results are illustrated as a heat map of significance values. Gene
co-expression analyses for each treatment were performed on
groups of genes with Q-values of#0.01 for at least one time point.
Co-expression modules were identified by weighted gene co-
expression network analysis (WGCNA) [21]. The results are
shown as a heat map of topological overlap matrices that indicate
co-expression modules. Functional enrichment of each identified
module was further evaluated by modular enrichment analysis
[22]. All analyses were performed using R suite (http://www.R-
project.org) and Cytoscape software [23].
Accession codes
All data are MIAME compliant and were deposited in the
MIAME compliant database National Center for Biotechnology
Information Gene Expression Omnibus (GEO; http://www.ncbi.
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Gene network analysis
The immune gene network was analyzed with Ingenuity
Pathway Analysis (IPA; IngenuityH Systems Inc., Redwood City,
CA, USA, www.ingenuity.com). IPA maps each gene within a
global molecular network developed from information contained
in the Ingenuity Pathways Knowledge Base. Gene networks are
generated algorithmically based on their connectivity in terms of
expression, activation, transcription, and/or inhibition. An IPA
‘‘network’’ is defined as a graphical representation of the
molecular relationships between genes, represented as nodes,
and biological relationships, represented as connecting lines
between nodes. All connections are supported by published data
stored in the Ingenuity Pathways Knowledge Base and/or
PubMed for mice. IPA ranks all genes based on their connectivity,
using a generalization of the node degree concept, which measures
the number of other genes to which a gene is connected. IPA-
based analysis has been successfully employed to elucidate
relationships and connections between differentially expressed
genes. For example, IPA elucidated the mechanisms of action of
CpG ODN in mouse spleens in addition to the mechanism of
action of the human yellow fever vaccine [11,24].
Assessment of cytokine proteins in the mouse vagina
Vaginas were collected at 4 h and 8 h after vaginal adminis-
tration of adjuvants. Tissue samples were placed immediately in
PBS containing 1.5 mM Pefabloc SC (Charles River Laboratories
Endosafe), 0.1 mg/ml soybean trypsin inhibitor (Sigma), 0.05 M
EDTA and 1% BSA and frozen at 270uC after weighing. Tissue
samples were thawed and permeabilized overnight at 4uC in PBS
with 2% (w/v) saponin (Sigma Aldrich). Samples were centrifuged
for 10 min at 12,000 rpm, and supernatants were collected.
Vaginal extracts were analyzed for IL-1b using a cytokine ELISA
kit (Duoset, R&D kit) according to the manufacturer’s recom-
mendations. TNF-a, IFN-c, IL-10 and IL-6 protein levels were
analyzed using a mouse inflammation CBA kit (BD Biosciences) on
a BD FACSCalibur, according to the manufacturer’s instructions
for BD CBA software. During data acquisition, a gate was set
around polystyrene beads. Data were analyzed using BD CBA
software, and standard curves were made using 4-parameter
logistic curve fitting, from which cytokine concentrations were
calculated. GraphPad Prism 4 software (GraphPad Software,
USA) was used for statistical analysis of protein expression. Results
are shown as the mean+standard error of mean (SEM). Statistical
significance of the variance between multiple groups was
calculated with one-way ANOVAs followed by Tukey’s multiple
comparison test with a 95% confidence interval (*: p#0.05,
**: p#0.01). Data shown are pooled from two separate
experiments.
Flow cytometry analysis of mouse vaginal cells
Local cell recruitment following vaginal administration of CpG
ODN or a-GalCer was examined by flow cytometry. Mouse
vaginas were aseptically removed at 12 h, 48 h and 72 h following
local administration of CpG ODN, a-GalCer or control diluents.
Vaginas (4 mice per group) were pooled in PBS, cut into small
pieces and incubated at 37uC on a magnetic stirrer for 30 min in
an EDTA/DTT solution containing 1 mM EDTA (Merck
KGaA), 1 mM DTT (Sigma-Aldrich), 10 mM HEPES (Sigma-
Aldrich), 1 mg/ml gentamicin sulfate (Sigma-Aldrich), and 5%
FCS (Sigma-Aldrich) in HBSS (Gibco Invitrogen Life Technolo-
gies). Tissues were then filtered through a 250-mm filter and
further disrupted for 2 h on a magnetic stirrer at 37uCi na
Liberase/DNase solution containing 0.6 mg/ml liberase (Roche),
0.1 mg/ml DNase I (Sigma-Aldrich), and 11 mM HEPES (Sigma-
Aldrich) in Iscoves modified medium (Sigma-Aldrich). The
remaining tissues were mashed and filtered through a 70-mm cell
strainer (BD Bioscience) to remove epithelial cells. After this step,
the cell suspensions were washed and counted.
Vaginal single cell suspensions of 100,000 cells/well were used.
Following blocking with CD16/32 for 20 min, vaginal cells were
stained for 20 min at 4uC with the following monoclonal
antibodies: goat a-mouse Gr1-PE (RB6-8C5), MHC-II-FITC
(M5/114.15.2), CD11c-PE (N418) and Cd11b-APC (M1/70)
(eBioscience). Samples were run on a BD FACSCalibur using
Cellquest Pro software (BD Bioscience). Analysis was performed
with FlowJo 7.5 (Tree Star, Inc.). Gates were set using live
leukocytes identified by forward, side scatter (FSC and SSC
respectively) and negative 7AAD (eBioscience) staining.
Results
Experimental design
We devised an experiment to analyze genome-wide transcrip-
tional alterations in mouse vaginas in response to vaginal
administration of the experimental CpG ODN or a-GalCer
adjuvants. Our previous studies showed that these adjuvants are
equally potent in the female mouse genital tract [7,8]. Four
animals from each group were treated i.vag. with a single dose of
either adjuvant or reagent diluents, which were PBS for the CpG
ODN group and PBS/Tween 0.5% for the a-GalCer group.
Then, the vaginas were excised and processed for RNA extraction
at 4 h, 24 h and 48 h post-treatment. Individual RNA samples
were then subjected to a whole mouse genome microarray
expression analysis. Normalized microarray expression data were
evaluated based on responses to the treatments by pair-wise
comparisons between treated and control mice. This evaluation
was done at each time point to avoid time difference effects.
Integrated analyses were employed to identify the signature
processes and pathways with respect to the individual adjuvant
and for comparisons between the two adjuvants.
Primary analysis of transcriptome data
We first performed an SVD of the transcriptome data to assess
the quality of our microarray experiments. Consistent alterations
in gene expression were noted among similarly treated mice when
compared to their respective controls in two independent
experiments. The largest separation of the data at each time
point after treatment was observed for the CpG ODN group when
compared to the a-GalCer group (Fig. 1A). A time-dependent
pattern in the spread of the data was observed for the CpG ODN
group, but only a minor difference in terms of time could be
detected among animals given a-GalCer. Intra-group as well as
inter-group data from the two differently treated control groups
(PBS and PBS/Tween) showed little variation (Figure S1).
A cut-off Q-value of less than 3 on a log scale (Q#0.001) was set
for analysis. As depicted in Figure 1B-C, CpG ODN induced rapid
alteration in the expression of 2,073 genes 4 h after administra-
tion. Alterations in gene expression peaked at 24 h, with 2,690
genes showing differential expression after CpG ODN adminis-
tration, but at 48 h, only 1,366 genes were differentially expressed.
A vast proportion of the significantly altered genes were altered at
multiple time points, with the most shared genes observed at 4 h
and 24 h. The kinetics of alterations in gene expression following
a-GalCer administration showed similar patterns, although the
overall response was weaker. Four hours after a-GalCer
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followed by 345 genes at 24 h and only 205 genes at 48 h. Several
genes with significant change in expression following a-GalCer
treatment were common between the different time points, with
the most common genes (117) observed at 24 h and 48 h.
Identification of top biological process engaged in
response to adjuvants
To identify the main biological processes targeted by CpG
ODN and a-GalCer, gene annotations were retrieved to identify
GO terms. The level of significance of each GO term was
evaluated using a reporter algorithm [19,20] to map the GO terms
(expressed as Q-values of transcriptome data). Hierarchical
clustering based on significant Q-values of GO terms belonging
to biological processes was performed to cluster response patterns
induced by the two adjuvants (Fig. 2A and Figure S2).
Clustering GO terms for up-regulated genes allowed us to
identify distinct regions with commonly and differentially
expressed GO terms for the two adjuvants, as summarized in
Fig. 2A and Figure S6. Two GO term regions showed high levels
of significance for both CpG ODN and a-GalCer and were chosen
for further analysis (Fig. 2A). GO terms from these common
regions were grouped into broader terms for biological processes
(Fig. 2B and Figure S6). Approximately half of the commonly up-
regulated GO terms were grouped into either ‘‘immune response’’
or ‘‘immune cell activation’’ (Fig. 2B). The majority of genes
within the highly significant GO term groups were up-regulated by
both adjuvants for at least one time point. Common significantly
up-regulated GO terms related to the immune system included
‘‘inflammatory response,’’ ‘‘cytokine production involved in
inflammatory response,’’ ‘‘cytokine-mediated signaling pathway,’’
‘‘response to cytokines stimulus,’’ and ‘‘chemotaxis’’ in addition to
several GO terms related to ’’immune response’’ and ‘‘antigen
processing and presentation’’. In addition, two regions containing
GO terms significantly up-regulated at 4 h and 48 h were
exclusively in the CpG ODN group (Figure S6A–B). At 4 h, the
largest sorted GO term group up-regulated solely in the CpG
ODN group was ‘‘cell signaling,’’ which contains ‘‘cell surface
pattern recognition receptor signaling pathways’’ (Figure S6B).
Importantly, several GO terms up-regulated at 48 h in the CpG
ODN group included negative regulation of ‘‘toll-like receptor
signaling pathway,’’ ‘‘innate immune response,’’ ‘‘chronic inflam-
matory response to antigenic stimulus’’ and ‘‘humoral immune
response’’ (Figure S6A). Two selected regions were identified for a-
GalCer (Figure S6C-D). At 4 h, the majority of GO terms
exclusive to the a-GalCer group belonged to metabolic processes,
while at 24 h, GO terms under ‘‘immune response’’ and ‘‘immune
cell activation’’ were up-regulated (Figure S6C). Several GO terms
exclusively up-regulated at 48 h after a-GalCer treatment involved
T cell responses such as ‘‘T cell co-stimulation,’’ ‘‘positive
regulation of CD4-positive, alpha beta T cell differentiation,’’
and ‘‘regulation of T cell receptor signaling pathway’’ (Figure
S6D).
The majority of the significant GO terms in down-modulated
genes were exclusive to the CpG ODN treated group and included
‘‘metabolic and cell cycle events,’’ ‘‘response to interferon
gamma,’’ ‘‘negative regulation of inflammatory response to
antigenic stimulus’’ and ‘‘positive regulation of myeloid cell
differentiation.’’ a-GalCer induced down-regulation of several
genes in the ‘‘metabolic processes and cell cycle events’’ GO term
group (Figure S2A).
Molecular pathway analysis
To understand the biological role of the differentially regulated
genes, pathway analysis was performed. A number of pathways
involved in innate immune response were identified among genes
up-regulated by both adjuvants (Fig. 3). These pathways included
‘‘innate immune signaling,’’ ‘‘TLR cascades,’’ and ‘‘interleukin-
Figure 1. Transcriptome primary data analysis of mouse vagina following vaginal delivery of adjuvants. Gene expression in the vagina
following CpG ODN (upper panel in red) or a-GalCer (lower panel in blue) delivery was monitored over time by microarray. Four biological replicates
were independently analyzed for each time-point. A Following normalization, the quality of the data in terms of consistency was assessed by singular
value decomposition. CpG ODN-treated mice (red) were compared to PBS controls (orange), and a-GalCer-treated mice (blue) were compared to PBS/
Tween controls (turquoise). Time points are characterized by plot symbols: circle=4 h, square=24 h and triangle=48 h. The figure shows two
dimensions, and a third dimension is illustrated by the size of the plot symbol. B Circular mapping plots showing alterations in gene expression over
time following adjuvant delivery on a chromosomal arrangement of transcripts based on Q-values on a log10 scale. C Venn diagram illustrating the
number of genes that are significantly (Q#0.001) differentially or commonly expressed by the adjuvants when compared to the respective controls at
different time points.
doi:10.1371/journal.pone.0020448.g001
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delivery of adjuvants. Up-regulated genes in the vagina at 4 h, 24 h and 48 h following local CpG ODN or a-GalCer administration were annotated
with GO terms for biological processes. GO terms were selected for mapping if they were significant in either of the two adjuvant treated groups for
at least one time point. A Color mapping and clustering of GO terms based on Q-values revealed distinct regions for exclusive and shared significantly
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volved in activation of classic and alternative complement
pathways were modulated by a-GalCer. Only the ‘‘initial
triggering of complement’’ term was identified in the CpG
ODN group. Another intriguing finding was the activation of
platelet associated pathways in the mouse vagina at 48 h after
adjuvant treatment. Pathways for ‘‘platelet activation’’ and
‘‘platelet aggregation’’ were triggered in the mouse vagina 48 h
after CpG ODN and a-GalCer administration. The majority of
the pathways identified from down-modulated genes were
involved in cell cycle events for both adjuvants and protein
metabolism and lipid metabolism for CpG ODN and a-GalCer,
respectively (Figure S3).
Gene co-expression module analysis
Several studies across a range of experimental conditions
support the notion that coordinated behavior in gene expression
indicates the presence of functional relationships between genes.
Further, several studies confirmed the versatility of co-expression
analysis for inferring gene functions, although co-expression does
not necessarily represent a regulatory relationship [25]. To
pinpoint correlation patterns among significantly altered tran-
scripts in the mouse vagina in response to adjuvants, we examined
co-expression of significantly altered gene transcripts (Q#0.01)
over time. Thus, a network construction program in which the
highest inter-connected genes are clustered into forming modules
was employed [21], and the results are summarized in Figure 4.
Two significant gene co-expression modules containing approxi-
mately 3,600 genes were identified for the CpG ODN group
(Fig. 4A). One significant gene co-expression module (Fig. 4B)
containing approximately 700 genes was identified for the a-
GalCer group. Functional terms were identified for genes within
each module and graphically displayed as integrated networks. In
the CpG ODN modules, the most connected functional groups
include ‘‘regulation of cytokine production,’’ ‘‘regulation of
neutrophil differentiation and chemotaxis,’’ ‘‘platelet activation
triggers,’’ ‘‘regulation of lymphocyte proliferation,’’ ‘‘MHC class I
peptide loading complex’’ and ‘‘proteasome.’’ In the a-GalCer
module, the major connected functional groups were ‘‘regulation
of innate immune response,’’ ‘‘antigen processing and presentation
of endogenous peptide antigen’’ and ‘‘proteasome activator
complex.’’ In addition, a number of smaller independent networks
of functional groups were observed in the a-GalCer module
(Fig. 4B).
IPA revealed ‘‘inflammatory response’’ as the top
biological function of both adjuvants
IPA was used to characterize the pattern of molecular
interactions of significantly up-regulated transcripts (Q#0.01) in
the mouse vagina in response to adjuvants. ‘‘Inflammatory
response’’ was identified as the top biological function at all
studied time points following administration of either CpG ODN
or a-GalCer. Networks illustrating the relationships between
significantly up-regulated genes involved in the inflammatory
response for each time point were generated and are illustrated in
Figure S4. Complicated networks of approximately 200 signifi-
cantly up-regulated genes involved in inflammatory response were
seen in the CpG ODN group at each time point studied. a-GalCer
generated a network of less than 50 genes, with relatively few
relationships at each time point. To acquire an overall picture of
the inter-related network of transcripts involved in inflammation,
genes whose expression was significantly up-regulated in at least
one of the three time points following adjuvant administration
were considered for network analysis, and the results are
summarized in Figure 5. A total of 345 gene transcripts were
assigned to ‘‘inflammatory response.’’ Of these genes, 336 genes
were targeted by CpG ODN, and 83 genes were targeted by a-
GalCer. Approximately one-third of these molecules were
localized to the cytoplasm, while another third were membrane/
receptor bound (Fig. 5). The remaining genes were divided
between the nucleus and extracellular regions, and the majority of
genes were identified as transcriptional regulators or cytokine/
chemokines. Within the inflammatory networks, significantly up-
regulated transcripts with the most interactions with other
significantly up-regulated transcripts, hereafter termed the main
interactors, were identified for the 2 adjuvants. Interestingly, IFN-
c, a critical cytokine gene involved in concerted innate and
adaptive immune responses, was identified as the main interactor
transcript for both adjuvants. Protein expression of IFN-c in the
mouse vagina was confirmed 8 h after vaginal administration of
either CpG ODN or a-GalCer (Fig. 5B). In addition, Tnf, Il-6, Il-
1b, Il-10 and MyD88 were shown to serve as major interactors
exclusively for CpG ODN. Protein expression levels of TNF-a, IL-
1b and IL-6 were only significantly up-regulated in the CpG
ODN-treated group when compared to the control group.
However, no significant increase in IL-10 protein levels could be
detected in any of the adjuvant-treated groups in comparison with
their respective control groups (Fig. 5B). These results indicate that
the two adjuvants can trigger up-regulation of genes involved in
‘‘inflammatory response.’’ This effect occurs, to a more limited
extent, in response to a-GalCer, but Ifng serves as the main
interactor of the inflammatory response network shared by both
adjuvants.
Discussion
This study strived to pinpoint signature molecules, pathways,
and processes involved in innate immune responses in the mouse
vagina following local administration of experimental mucosal
adjuvants. CpG ODN and a-GalCer were selected for this study
based on our previous findings that these adjuvants, when
delivered i.vag. together with a HSV-2 gD protein, elicited
comparable levels of protective immunity in the female genital
tract against genital herpes [7,8]. Complex vaginal tissues were
used for analysis because they offer the unique advantage of
monitoring alterations in gene expression related to multifaceted
cell-to-cell interactions under physiological conditions.
The kinetics and magnitude of the overall alterations in gene
expression differed between the two types of adjuvants. While
CpG ODN induced a quick change in expression of 3,830 genes,
with 1,366 genes remaining elevated at 48 h, the response to a-
GalCer was more modest and transient, with a total of 602 genes
modulated over all studied time points (Fig. 1B and C).
In addition to innate immune responses and inflammatory
responses, a number of biological processes associated with antigen
processing and presentation and T cell activation that are
expressed GO terms. B GO terms from the two regions showing high significance for both adjuvants were jointly grouped into wider bio-functional
terms. Colors range from green to red, indicating increasing Q-value, and the angle of the arrows represents the proportion of genes within that GO
term that are up- or down- regulated. A completely vertical arrow pointing upward indicates 100% of the genes annotated to that specific GO term
were up-regulated, while a horizontal arrow means that 50% of the genes were up-regulated and that 50% of the genes were down-regulated.
doi:10.1371/journal.pone.0020448.g002
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commonly induced by the two adjuvants (Fig. 2B). Inflammatory
response was identified by IPA as the main bio-function shared by
both CpG ODN and a-GalCer (Fig. 5A and Figure S4). These
results extend our previous real time RT-PCR results, in which the
expression of more inflammatory cytokine and chemokine genes
were more robustly expressed in the mouse vagina after local
delivery of CpG ODN when compared to a-GalCer [13]. IPA has
successfully been used to identify relationships and connections
between differentially expressed genes. For example, IPA demon-
strated the mechanisms of action of CpG ODN in mouse spleens
and elucidated the mode of action of the human yellow fever
vaccine [11,24]. Although both adjuvants induced an inflamma-
tory response, the characteristics of the responses differed. CpG
ODN modulated the expression of approximately four times as
many inflammatory genes when compared to a-GalCer (Fig. 5A).
Ifng was the common interactor in the inflammatory responses
elicited by both adjuvants, but Tnf was exclusively induced by
CpG ODN (Fig. 5A). A recent microarray and bioinformatic study
on gene expression identified Tnf and Ifng as the main inducers in
the murine spleen following intra-peritoneal injection of CpG
ODN [11].
Our co-expression studies identified networks of ‘‘regulation of
neutrophils differentiation’’ and ‘‘positive regulation of neutrophil
chemotaxis,’’ which contained highly inter-connected genes
among CpG ODN-induced networks (Fig. 4A). The neutrophil-
attracting ELR-CXC chemokines Cxcl1 and Cxcl2 genes were
also highly up-regulated in the vagina of CpG ODN-treated mice
(Fig. 5A). In line with this observation, our flow cytometry analysis
could detect more than a ten-fold increase in the percentage of
neutrophils (CD11b
+, Gr-1
+, MHC II) in the vagina 12 h after
CpG ODN administration. Notably, the levels of neutrophil
infiltration in the vagina were reduced at 48 h and returned to the
same basal levels as the controls at 72 h (Figure S5). We also
showed that the percentage of macrophages (MHC II
+, CD11b
+,
CD11c
-) and DCs (MHC II
+, CD11b
+, CD11c
+) increased in the
mouse vagina after administration of CpG ODN or a-GalCer.
These findings are consistent with a previous study that showed
expansion of tissue neutrophils, macrophages and DCs following
mucosal CpG ODN delivery [26]. Whereas triggering an
inflammatory response is considered to be required for adjuvants
to exert their function, excessive inflammation may lead to serious
tissue damage. In fact, our previous results demonstrate that CpG
ODN, but not a-GalCer, causes massive inflammatory cell
infiltration into the mouse vagina and leads to damage to the
mouse vaginal epithelium [13].
We employed an integrated analysis of the transcriptome data
to pinpoint signature pathways and processes that could not have
Figure 4. Co-expression and module network analysis of significantly altered genes significantly in the mouse vagina in response
to local administration of adjuvants. Genes identified as having significantly altered expression, i.e., a Q-value of#0.01 following A CpG ODN or
B a-GalCer administration were analyzed for co-expression. Rows and columns of the heat map represent the same genes. The level of co-expression
(connectivity) between genes is displayed by color intensity in the heat map, ranging from no connectivity in light yellow to a strong connection in
red. High connectivity modules, shown as yellow, green and blue bars, were identified, and rectangular frames show functional terms and inter-
relationships of annotated biological terms of the genes within each module. For a larger version of this figure, refer to Figure S7.
doi:10.1371/journal.pone.0020448.g004
Figure 3. Adjuvant induced molecular pathways in the mouse vagina. Mapping and clustering of CpG ODN- or a-GalCer-induced pathways
in the vagina based on Q-values. Pathways were selected for mapping if they demonstrated significance (Q#0.001) in either of the two adjuvant-
treated groups for at least one time point.
doi:10.1371/journal.pone.0020448.g003
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integrated approach has been recently used to identify the
molecular effects of diet on metabolism in mice [27]. An
intriguing finding that emerged from our integrated analysis was
the co-expression of genes involved in proteasome activation and
MHC class I peptide loading in the vagina of mice given CpG
ODN or a-GalCer. Given the critical importance of proteasome
and MHC class I loading events in the development of cytotoxic
T cell CTL response [28], it is likely that these 2 adjuvants can
trigger a CTL response following vaginal administration.
Interestingly, we could show that female C57Bl/6 mice
immunized i.vag. with the model antigen ovalbumin in combi-
nation with CpG ODN or a-GalCer (same doses of adjuvants
used in the current study) developed a potent ovalbumin
Figure 5. Adjuvant-induced inflammatory response bio-function in the mouse vagina. Following vaginal administration of CpG ODN or a-
GalCer, Ingenuity Pathway Analysis identified ‘‘Inflammatory response’’ as the top bio-function network among significantly up-regulated (Q#0.01)
genes. A A network showing cellular localization and known relationships between genes involved in the inflammatory response. Genes are colored
based on their induction by CpG (red), a-GalCer (blue) or both adjuvants (purple). B Key interactor genes are highlighted in A and were confirmed at
the protein level by ELISA (IL-1b) and CBA (IL-6, TNF, IL-10 and IFN-c). Results shown are pooled from two independent experiments. Bars show
mean+SEM (*: p#0.05, **: p#0.01).
doi:10.1371/journal.pone.0020448.g005
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that drained the genital tract (Lindqvist M et al., un-published
results).
Both common and different molecular pathways were triggered
in the vagina in response to adjuvants. Thus, classical and
alternative pathways of complement activation were induced by a-
GalCer. However, the C3 molecule was significantly up-regulated
in the vagina in response to both CpG ODN and a-GalCer. The
involvement of the complement system in modulating T- and B
cell responses by bridging innate and adaptive immunity has been
previously established [29]. Interestingly, the C3 molecule has
been shown to function as a molecular adjuvant to enhance
humoral immune responses to co-administered antigens in mice
[30]. Pathways involved in ‘‘platelet activation and aggregation’’
and ‘‘platelet activation triggers’’ were targeted by CpG ODN and
a-GalCer, respectively. Platelets play an important role in
inflammation in addition to their role in thrombosis [31]. Thus,
through interactions with endothelial cells, platelets induce NF-kB
signaling and enhance neutrophil migration into tissue [32,33].
Notably, up-regulation in expression of genes involved in
inhibitory receptor programmed death 1 (PD-1) signaling, which
has an essential role in controlling excessive inflammatory
response [34], was only observed in the vaginas of a-GalCer
treated mice (Fig. 3). This expression pattern may explain the
more controlled inflammatory response elicited in the vagina in
response to a-GalCer. Another pathway induced only by CpG
ODN was glycolysis. TLR agonists can induce glycolysis and
thereby regulate DC activation [35]. Furthermore, the end
product of glycolysis, lactate, is an important component in
maintaining the acidic pH of the vagina; therefore, it contributes
to the innate defenses of the female genital tract [36].
In conclusion, through employment of integrated analyses of
transcriptome data, we identified signature pathways, processes
and networks shared by two classes of promising mucosal
adjuvants, namely the TLR9 agonist CpG ODN and the iNKT
cell agonist a-GalCer. To our knowledge, this is the first integrated
genome-wide transcriptome analysis on the effect of immuno-
modulatory adjuvants on immunological functions and pathways
in the mammalian female genital tract. These results provide new
insights into understanding the mechanism of action of mucosal
adjuvants in the female genital tract and therefore may inform
rational development of effective vaccine adjuvant and immuno-
therapeutic approaches to counter STIs.
Supporting Information
Figure S1 Singular value decomposition (SVD) analysis
for validation of microarray data. Alterations in gene
expression in the vagina following administration of CpG ODN
(red), a-GalCer (blue) or the PBS (orange) and PBS/Tween
(turquoise) controls were monitored over time by microarray.
Following normalization, the quality of the data in terms of
consistency was assessed by SVD. Time points are characterized
by the following plot symbols: circle=4 h, square=24 h and
triangle=48 h. The figure shows two dimensions, and a third
dimension is illustrated by the size of the plot symbol.
(EPS)
Figure S2 Annotation and expression of biological
processes. Down-regulated genes in the vagina at 4 h, 24 h
and 48 h following CpG ODN or a-GalCer administration were
annotated to GO terms for biological processes. GO terms that
were significant (Q#0.001) for either adjuvant and any time point
were color mapped and clustered based on Q-values.
(EPS)
Figure S3 Down-modulated pathways in the murine
vagina in response to vaginal delivery of adjuvants.
Mapping and clustering of CpG ODN or a-GalCer down-
modulated pathways in the vagina based on Q-values. Pathways
were selected for mapping if they demonstrated significance
(Q#0.001) in either of the two adjuvant-treated groups for at least
one time point.
(EPS)
Figure S4 Inflammatory networks and major interactor
genes identified in the murine vagina in response to
vaginal delivery of adjuvants. Ingenuity Pathway Analysis
identified ‘‘Inflammatory response’’ as a top bio-function following
vaginal administration of CpG ODN or a-GalCer in the mouse
vagina. Networks show relationships between significantly up-
regulated genes (Q#0.01) at each time-point, where full lines are
direct relationships and dotted lines indicate indirect relationships.
Color labels ranging from bright pink to red are representative of
the degree of the increase in fold change expression values
compared to the respective control groups (darker reds represent
higher gene expression levels).
(EPS)
Figure S5 Recruitment of innate immune cells to the
mouse vagina following vaginal administration of adju-
vants. Groups of mice were i.vag. administered a single dose of
CpG ODN, a-GalCer, PBS or PBS/Tween 5%. After 12 h, 48 h
and 72 h following vaginal delivery of CpG ODN or a-GalCer,
vaginas were excised and pooled, and cells were extracted. Cells
were stained for cell markers, and flow cytometry was used to
quantify the percentage of: A and C neutrophils expressing
CD11b
+, Gr-1
+, and MHC II
-; A and E DC-like cells expressing
CD11b
+, Gr-1
+, and MHC II
+; B and D macrophages, identified
as MHC II
+, CD11b
+, CD11c
- cells; and B and F conventional
DCs, identified as being MHC II
+, CD11b
+, and CD11c
+. Gates
were set on live leukocytes, and the plots in the lower rows of A
and B were gated on the double positive cells in the upper row.
Plots shown are representative of 12 h post-treatment from two
independent experiments with pooled samples from 4 mice in each
group and time point. Numbers represent the percentage of the
gated population, while numbers in parenthesis in the lower row
show abundance of live leukocytes.
(EPS)
Figure S6 Grouping of biological processes identified in
the murine vagina in response to local administration of
adjuvants. Broader functional grouping of GO terms for
significantly induced biological processes by CpG ODN and a-
GalCer. Panels A and B display CpG ODN-specific GO terms with
the highest significanceat 48 h and 4 h,while Cand D are a-GalCer
specific. Colors range from green to red to indicate increasing Q-
value, and the angle of the arrows represents the proportion of genes
within that GO term that are up- or down-regulated. A completely
vertical arrow pointing upward indicates 100% of the genes
annotated with that specific GO term were up-regulated, while a
horizontal arrow means that 50% of the genes were up-regulated.
(EPS)
Figure S7 Co-expression and module network analysis
of significantly altered genes significantly in the mouse
vagina in response to local administration of adjuvants.
Genes identified as having significantly altered expression, i.e., a
Q-value of#0.01 following A CpG ODN orB a-GalCer
administration were analyzed for co-expression. Rows and
columns of the heat map represent the same genes. The level of
cohyphen;expression (connectivity) between genes is displayed by
Molecular Signatures of Vaginal Adjuvants
PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e20448color intensity in the heat map, ranging from no connectivity in
light yellow to a strong connection in red. High connectivity
modules, shown as yellow, green and blue bars, were identified,
and rectangular frames show functional terms and interrelation-
ships of annotated biological terms of the genes within each
module. This supporting figure is a larger version of Figure 4.
( )
Table S1 List of Q-values, log 2 fold changes, the
pathway and GO networks including their associated
gene members used for the integration analysis of the
transcriptomic data.
(XLSX)
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